ABSTRACT Pericardial effusion (PEF) in PAH may be a marker of worsening disease or associated with autoimmune conditions. Sotatercept was not initially reported as associated with the development or progression… Click to show full abstract
ABSTRACT Pericardial effusion (PEF) in PAH may be a marker of worsening disease or associated with autoimmune conditions. Sotatercept was not initially reported as associated with the development or progression of PEF. We describe PAH patients taking sotatercept who were found to have new or worsening PEF and examine associated comorbidities.
Keywords:
pah;
taking sotatercept;
progressive pericardial;
pericardial effusion;
pericardial effusions
Journal Title: Pulmonary Circulation
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pulmonary Circulation
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!